Evaluation of Tc-99m mercaptoacetyltriglycine in patients with impaired renal function.
Evaluation of Tc-99m mercaptoacetyltriglycine in patients with impaired renal function.
复制标题
Tc-99m 巯基乙酰基三甘氨酸在肾功能受损患者中的评价。
DOI：
10.1148/radiology.162.2.2948212
复制
发表时间：
1987
期刊：
影响因子：
19.7
通讯作者：
Milton,W
中科院分区：
文献类型：
--
作者：
TaylorJr,A;Eshima,D;Christian,PE;Milton,W
锝-99 m巯基乙酰基三甘氨酸（MAG_3）是一种新的放射性药物，在动物和健康志愿者中显示出与~（131）I-O-碘马尿酸（OIH）相似的生物学特性。无论血清肌酐水平如何，Tc-99 m MAG 3图像均为上级。OIH和MAG 3的30分钟血液清除率无显著差异。MAG 3蛋白结合率（78.6%）大于OIH（53.1%）（P ≤ 0.01），MAG 3的分布容积（7.06升）小于OIH（10.78升）（P ≤ 0.01）。在6例患者中，两种药物的30分钟尿排泄基本相同。使用皮质和全肾感兴趣区域，MAG 3的肾图曲线达到峰高的时间比OIH更快（P小于或等于0.02）。总之，初步结果表明，Tc-99 m MAG 3在肾功能受损患者中表现良好，很可能是OIH的可接受替代品。目前正在对试剂盒制剂进行临床评价。
Technetium-99m mercaptoacetyltriglycine (MAG3), a new radiopharmaceutical shown to have biological properties similar to iodine-131 o-iodohippurate (OIH) in animals and healthy volunteers, was compared with OIH in 15 patients with varying degrees of renal impairment. The Tc-99m MAG3 images were uniformly superior, regardless of the serum creatinine level. There was no significant difference in the 30-minute blood clearance of OIH and MAG3. MAG3 protein binding (78.6%) was greater than that of OIH (53.1%) (P less than or equal to .01), and the volume of distribution of MAG3 (7.06 liters) was less than that of OIH (10.78 liters) (P less than or equal to .01). In six patients the 30-minute urinary excretion of the two agents was essentially identical. The time to the peak height of the renogram curves was more rapid for MAG3 than for OIH using both cortical and whole-kidney regions of interest (P less than or equal to .02). In summary, preliminary results suggest that Tc-99m MAG3 performs well in patients with impaired renal function and may well be an acceptable replacement for OIH. A kit formulation is currently undergoing clinical evaluation.